aTyr Pharma (LIFE) versus Biogen (BIIB) Critical Comparison

Share on StockTwits

aTyr Pharma (NASDAQ: BIIB) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Profitability

This table compares aTyr Pharma and Biogen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
aTyr Pharma N/A -74.02% -52.93%
Biogen 23.06% 38.17% 20.41%

Valuation & Earnings

This table compares aTyr Pharma and Biogen’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
aTyr Pharma N/A N/A -$48.20 million ($1.87) -0.37
Biogen $12.27 billion 5.63 $2.54 billion $21.81 15.74

Biogen has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

aTyr Pharma has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Insider and Institutional Ownership

65.8% of aTyr Pharma shares are owned by institutional investors. Comparatively, 89.4% of Biogen shares are owned by institutional investors. 25.0% of aTyr Pharma shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for aTyr Pharma and Biogen, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
aTyr Pharma 1 2 1 0 2.00
Biogen 0 9 20 0 2.69

aTyr Pharma currently has a consensus target price of $1.58, suggesting a potential upside of 129.47%. Biogen has a consensus target price of $375.52, suggesting a potential upside of 9.39%. Given aTyr Pharma’s higher possible upside, equities research analysts plainly believe aTyr Pharma is more favorable than Biogen.

Summary

Biogen beats aTyr Pharma on 10 of the 13 factors compared between the two stocks.

aTyr Pharma Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.

Biogen Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply